Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) | PAR 21 053

Opportunity Information: Apply for PAR 21 053

The Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases funding opportunity (PAR-21-053) is a National Institutes of Health (NIH) discretionary grant program that uses the R01 research project grant mechanism to support clinical observational research focused on musculoskeletal, rheumatic, and skin diseases. The key purpose is to fund well-designed observational studies in humans that can advance understanding of these conditions through approaches like natural history studies, cohort or case-control studies, registry-based analyses, and other non-interventional clinical research strategies. A central restriction is built into the title itself: clinical trials are not allowed under this announcement, meaning projects that prospectively assign human participants to an intervention (for example, a drug, device, procedure, behavioral treatment, or other assignment intended to test effects on health outcomes) would not fit this opportunity. In practice, the program is meant for research that observes and measures rather than intervenes, typically emphasizing clinical characterization, risk factors, outcomes, disease progression, phenotyping, epidemiology, and similar aims that do not involve assigning participants to treatment conditions.

This opportunity is offered as a grant (FundingInstrumentType: Grant) within the health category and is associated with CFDA number 93.846. While the public listing you provided does not spell out every scientific priority area, the title and NIH institute focus indicate the scope is centered on conditions affecting bones, joints, muscles, connective tissue, immune-mediated rheumatic disease, and skin biology and disease, with an emphasis on clinical, patient-oriented observational work rather than laboratory-only studies or interventional trials. Because it is an R01, applicants are generally expected to propose a mature, hypothesis-driven project with clear aims, rigorous methods, feasible recruitment or data access plans, strong statistical approaches, and a clear path to generating meaningful knowledge that can inform future research, clinical understanding, or subsequent interventional efforts.

A broad range of organizations may apply. Eligible applicants explicitly include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; Native American tribal organizations other than federally recognized tribal governments; nonprofit organizations with or without 501(c)(3) status (as long as they are not institutions of higher education when categorized that way); for-profit organizations other than small businesses; small businesses; and other applicant types. The opportunity also highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; eligible federal agencies; regional organizations; Indian/Native American Tribal Governments other than federally recognized entities; and U.S. territories or possessions. This mix signals NIH intent to encourage applications from diverse institutional settings, including community-based and minority-serving institutions that may have unique access to patient populations, registries, or real-world clinical settings relevant to these diseases.

There are important geographic and foreign participation rules. Non-domestic (non-U.S.) entities, including foreign organizations and foreign institutions, are not eligible to apply directly as the applicant organization. Non-domestic components of U.S. organizations are also not eligible to apply. However, foreign components are allowed as defined by the NIH Grants Policy Statement, which typically means a U.S. applicant organization can include certain elements of work conducted outside the U.S. when scientifically justified and appropriately structured, while still keeping the prime applicant as a domestic entity and staying within NIH policy requirements.

From the administrative details provided, the original closing date listed is 2023-11-03, the opportunity was created on 2020-11-13, and an award ceiling of 250,000 is shown in the source data. The listing does not specify an expected number of awards in the field you shared, so applicants would usually look to NIH program guidance and available appropriations to understand competitiveness and likely funding volume. Because NIH R01 budgets can vary depending on the specific FOA terms and institute policies, applicants should treat the ceiling figure shown here as a constraint specific to this announcement’s listing and verify budget caps and direct cost limits in the full FOA text and NIH application instructions before building a budget.

Overall, this grant opportunity is best suited for research teams that can conduct rigorous human observational research in musculoskeletal, rheumatic, and skin diseases, using strong study designs and analytic plans, without crossing into clinical trial territory. It is particularly relevant for applicants proposing cohorts, longitudinal follow-up, outcomes research, registries, or comparative observational analyses that can clarify disease course, identify predictors of outcomes, refine clinical phenotypes, or generate evidence that sets the stage for future mechanistic or interventional work.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846.
• This funding opportunity was created on 2020-11-13.
• Applicants must submit their applications by 2023-11-03. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $250,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 21 053

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: